Emerson Electric (EMR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
12 Dec, 2025Executive summary
The 2026 Annual Meeting will be held virtually on February 3, 2026, with shareholders voting on director elections, executive compensation, auditor ratification, and a proposal to declassify the board.
The company accelerated its transformation into a global automation leader, highlighted by the acquisition of Aspen Technology and National Instruments, and divestiture of Copeland.
Strong financial performance in 2025 included 3% net sales growth, 43% EPS growth, 12% free cash flow growth, and $2.4B returned to shareholders.
The company targets returning $10B to shareholders by 2028 through dividends and $6B in share repurchases.
Voting matters and shareholder proposals
Shareholders will vote on three director nominees, an advisory say-on-pay vote, ratification of KPMG as auditor, and an amendment to declassify the board.
The board recommends voting FOR all proposals, including the declassification amendment, which requires 85% approval.
Proxy access allows up to 20 shareholders holding 3% for 3 years to nominate directors in the proxy.
Board of directors and corporate governance
The board consists of 10 directors, 90% independent, with an average tenure of 7.8 years and 40% joining in the last 5 years.
Board leadership is separated, with an independent chair and CEO.
The board is divided into three classes, but a proposal to declassify is up for vote.
Board refreshment and director term limits are in place; directors may not stand for re-election after 15 years or age 72 without board approval.
Committees include Audit, Compensation, Governance and Nominating, Technology and Environmental Sustainability, and Executive.
Latest events from Emerson Electric
- AI-driven software growth and robust U.S. demand fuel strong performance and future outlook.EMR
Citi's Global Industrial Tech & Mobility Conference 202618 Feb 2026 - Strong order growth, innovation, and high margins drive a positive outlook and investor confidence.EMR
Barclays 43rd Annual Industrial Select Conference17 Feb 2026 - Q1 2026 saw 4% sales growth, 6% EPS growth, and raised guidance, driven by automation demand.EMR
Q1 20264 Feb 2026 - Targeting $21B sales, 30% EBITA margin, $8.00 EPS, and $10B shareholder returns by 2028.EMR
Investor Update3 Feb 2026 - Director elections and key proposals passed; board declassification did not meet approval threshold.EMR
AGM 20263 Feb 2026 - Q3 sales and adjusted EPS up 11%, Copeland exit boosts debt reduction and guidance raised.EMR
Q3 20242 Feb 2026 - Record FY24 growth, portfolio actions, and $2B buyback set up strong 2025 outlook.EMR
Q4 202416 Jan 2026 - Record margins, 13% EPS growth, and robust cash flow with AspenTech deal pending.EMR
Q1 20259 Jan 2026 - Key votes include board declassification, director elections, and executive pay approval.EMR
Proxy Filing12 Dec 2025